RBC flags this biopharma stock as recession-ready, with stellar upside potential hiding in plain sight.
Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder (MDD) with and without severe excessive daytime...
Alkermes plc ALKS announced that it has initiated the phase II Vibrance-3 study, evaluating the novel, investigational and oral orexin 2 receptor agonist, ALKS 2680, in adults with idiopathic hypersomnia...
Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol (brand...
As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded...